Zimmer Biomet Holdings Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its iodine-treated total hip replacement system, marking the first time a Zimmer Biomet product has received this designation. This system, which incorporates a controlled-release iodine surface treatment to help prevent periprosthetic joint infections in high-risk patients, was previously approved by Japan's Pharmaceutical and Medical Devices Agency (PMDA). The FDA Breakthrough Device Designation will expedite regulatory review in the U.S., allowing Zimmer Biomet to work closely with the agency to bring this innovative technology to patients. No other organizations were mentioned as recipients of this regulatory milestone.